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Background. One of the big roadblocks in development of HIV-1/AIDS vaccines is the enormous diversity of HIV-1, which
could limit the value of any HIV-1 vaccine candidate currently under test. Methodology and Findings. To address the HIV-1
variation, we designed a novel T cell immunogen, designated HIVCONSV, by assembling the 14 most conserved regions of the
HIV-1 proteome into one chimaeric protein. Each segment is a consensus sequence from one of the four major HIV-1 clades A,
B, C and D, which alternate to ensure equal clade coverage. The gene coding for the HIVCONSV protein was inserted into the
three most studied vaccine vectors, plasmid DNA, human adenovirus serotype 5 and modified vaccine virus Ankara (MVA), and
induced HIV-1-specific T cell responses in mice. We also demonstrated that these conserved regions prime CD8
+ and CD4
+ T
cell to highly conserved epitopes in humans and that these epitopes, although usually subdominant, generate memory T cells
in patients during natural HIV-1 infection. Significance. Therefore, this vaccine approach provides an attractive and testable
alternative for overcoming the HIV-1 variability, while focusing T cell responses on regions of the virus that are less likely to
mutate and escape. Furthermore, this approach has merit in the simplicity of design and delivery, requiring only a single
immunogen to provide extensive coverage of global HIV-1 population diversity.
Citation: Le ´tourneau S, Im E-J, Mashishi T, Brereton C, Bridgeman A, et al (2007) Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine. PLoS
ONE 2(10): e984. doi:10.1371/journal.pone.0000984
INTRODUCTION
Despite twenty-five years of global effort, an effective vaccine against
the human immunodeficiency virus type 1 (HIV-1) remains elusive.
Induction of broadly neutralizing antibodies against HIV-1 is very
difficult, yet it is the key to all other protective anti-viral vaccines[1].
Therefore consideration of HIV-1 vaccine candidates that stimulate
cellular immunity has been the focus of many recent vaccines[2].
Although recent advances in vector design have generated optimism
in this field[3,4], these technologies still need to address the extreme
variability of HIV-1, whereby co-circulating viruses may differ in
over 20% of their proteome[5,6]. Thus, while novel vectors and
heterologous prime-boost combinations are getting better at in-
ducinghigherfrequenciesofHIV-1-specificTcells,lessattentionhas
been paid to how these vaccines can elicit T cells capable of
recognizing multiple HIV-1 variants.
ThereareseveralapproachesfordealingwiththeHIV-1diversity.
One optimistic view is that a single clade may induce sufficiently
cross-reactive T-cell responses to protect against other variants of
both the same and heterologous clades. The choice of a natural
isolate can be based on having the closest sequence to all others, or
pickingastrainderived fromacuteinfectionand arguingthatthereis
a convergence of viral sequences during transmission[7]. However,
even if a single variant elicits responses that confer some cross-
reactive protection, such protection is likely to be only partial and
thus it is well worth attempting to design vaccine immunogens with
enhanced cross-reactive potential. Although there are numerous
reports of cross-clade reactive HIV-1-specific CD8
+ Tc e l l
responses[8–12], use of unphysiologically high concentrations of
variant peptides make the biological relevance of many of these
results uncertain. In contrast, there are ample examples of highly
specific T cell receptors sensitive to single amino acid (aa)
changes[13–19], as well as compelling evidence of HIV-1 variants
escaping existing T cell responses in infected individuals by single
mutations in epitopes[2,20–22]. In vitro, systematic studies employ-
ing all possible single aa substitutions in each position of an MHC
class I epitope indicated that as few as one third of such epitope
variants were recognized by a given T cell receptor[13,19]. These
results are in agreement with theoretical predictions proposed for
cross-recognition of MHC class I-presented peptides by T cell
receptors[23]. Thus the use of a single natural isolate for a vaccine
has a high risk of not protecting against a different clade, nor against
many variants of the same clade.
A second approach to HIV-1 diversity derives vaccine immuno-
gensfrom‘centralized’sequences,whichemployconsensus/average,
or centre-of-the-tree[24] sequences or extrapolated aa to a common
clade or group ancestor[5]. Centralized sequences are designed to
minimize the sequence differences between a vaccine immunogen
and circulating viruses[5,24–26]. So far they have proven immuno-
genic and able to elicit T cell responses in small animal
studies[24,27–29] and clinical trials[30–32], providing experimental
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immunogens for the entire group M are promising in that initial
immunogenicity studies in mice yielded T-cell responses that were
comparable to within-clade responses for many clades[29], however,
this strategy may be stretched too far for optimal coverage of CD8
+
T cell epitope variants of the whole group M[18,19,33].
In a third approach, vaccines deliver a cocktail of immunogens
derived from different clades[34–36]. While initial results have
been encouraging and responses to each antigen in the cocktail
were observed[36], attention still needs be paid to possible
immune interference, such as epitope antagonism, between
different, but closely related peptide sequences in the vaccine,
which may be limiting responses to some epitopes. Antagonism of
T cell responses by altered epitope peptide ligands has been
demonstrated both in vitro[37,38] and in vivo[18,39–42]. It can
occur when a host capable of mounting a response to an agonist
epitope is simultaneously exposed to an antagonist epitope variant,
which interferes with the induction of the T cell response to the
agonist epitope and leads to a defective response. Thus, the
breadth of responses induced by cocktail approaches should be
carefully monitored when such vaccines are used[18].
A fourth approach uses computational methods for assembling
a polyvalent vaccine candidate that optimize the coverage of T cell
epitopes. ‘Mosaic’ immunogens[43] are based on intact proteins and
retain the probability for natural processing and presentation of T
cell epitopes. Their potential problems are similar to those of other
cocktails of natural proteins, i.e. immune interference and inclusion
of both variable and conserved regions, whereby responses to
variable regions may draw attention away from potentially more
useful conserved targets. The impact of these processes will be only
resolved in vaccine studies. An alternative means of designing
immunogens contending with the HIV-1 variation is the COT+
method[44], which combines a central sequence with a set protein
fragments designed to help cover diversity.
Here, we describe a further alternative that may have
considerable advantages. We describe the construction and
experimental testing in mice and humans of a novel multi-clade
immunogen derived only from highly conserved regions of the
HIV-1 consensus proteome, which was designed to provide
extensive coverage of the principle HIV-1 clades A, B, C and D,
while minimizing the possible occurrence of the epitope in-
terference. It has the potential considerable advantage of focusing
the T cell responses on the most conserved parts of the virus and
thus overcoming the usual patterns of immunodominance, while
making it difficult for the virus to escape without a likely significant
cost to its fitness. This approach has also merit in the simplicity of
design and delivery, requiring only a single immunogen to provide
extensive coverage of global HIV-1 population diversity.
METHODS
Preparation of the pTH.HIVCONSV and
pTH.HIVCONSVdH DNA vaccines
The synthetic gene coding for HIVCONSV (GeneArt) was subcloned
intoplasmidpTH[45]andthecodonscodingfortheHepitopewere
deleted using a PCR assembly to generate pTH.HIVCONSVdH. The
plasmid DNA for immunizations was prepared using the Endo-Free
Gigaprep (Qiagen) and stored at 220uC until use.
Preparation of the AdHu5.HIVCONSV and
AdHu5.HIVCONSVdH vaccines
Recombinant adenoviruses were obtained using the AdEasy
TM
Adenoviral Vector System (Stratagene), following the manufac-
turer’s instructions. Both adenoviruses expressed the green
fluorescent protein as a marker.
Preparation of the MVA.HIVCONSV and
MVA.HIVCONSVdH vaccines
Recombinant MVAs (rMVAs) were made as described previously
[46]. Briefly, chicken embryo fibroblast (CEF) cells grown in
Dulbeco’s Modified Eagle’s Medium supplemented with 10%
FBS, penicillin/streptomycin and glutamine (DMEM 10) were
infected with parental MVA at MOI 1 and transfected using
Superfectin (Qiagen) with 3 mg of pSC11.HIVCONSV or
pSC11.HIVCONSVdH carrying also the b-galactosidase gene as
a marker. Two days later, the total virus was harvested and used to
re-infect CEF cells. rMVAs were subjected to five rounds of plaque
purification, after which a master virus stock was grown, purified
on a 36% sucrose cushion, titered and stored at –80uC
until use.
Immunofluorescence
Six-well tissue culture plates containing sterile microscope cover-
slips treated with 0.01% poly-L-lysine (Sigma) were seeded with
1610
5 cells/well of HEK293T. After 12–24 h, cells reached 80%
confluency and were transfected with 5 mg of a selected plasmid
using the Superfectin (Qiagen), according to the manufacturer’s
recommendations, or infected with a selected recombinant viral
vector at MOI 1 or 10. Cells were then incubated for 18–24 h,
fixed with 0.5% formaldehyde, washed with PBS, their mem-
branes perforated with 50% ethanol for 5 min, 70% ethanol for
10 min, and 50% ethanol for 3 min. Cells were washed again and
blocked overnight with 2% FCS in PBS (FCS/PBS) at 4uC. The
FCS/PBS solution was replaced by a 1/200 working dilution of
a primary mouse monoclonal antibody against the Pk tag (Serotec)
in FCS/PBS and incubated for 3–18 h at 4uC. Cells were
subsequently washed three times with PBS, and incubated with
a 1/500 dilution of the Alexa fluor 594-conjugated secondary
chicken anti-mouse monoclonal antibody (Molecular Probes) in
FCS/PBS for 2 h at room temperature or for 3–18 h at 4uC.
Alternatively, a FITC-conjugated mouse monoclonal antibody
against the Pk tag was used at a 1/500 dilution in FCS/PBS, and
incubated for 2 h at room temperature or 3–18 h at 4uC. The cells
were then washed three times with PBS, mounted on a microscope
slide with Vectashield DAPI nuclear stain (Vector Laboratories)
and photographed on a Zeiss fluorescence microscope.
Mice
For all animal experiments, groups of four 5- to 8-week-old female
BALB/c or HHD mice were used. All animal procedures and care
were approved by a local Ethical Committee and strictly
conformed to the UK Home Office Guidelines.
Mouse immunizations and preparation of
splenocytes
Under general anaesthesia, mice were immunized i.m. with 100 mg
of pTH.HIVCONSV DNA, or 10
6 PFU of AdHu5.HIVCONSV or
10
6 PFU of MVA.HIVCONSV. On the day of sacrifice, spleens
were removed and pressed individually through a cell strainer
(Falcon) using a 5-ml syringe rubber plunger. Following the
removal of rbc with Rbc Lysis Buffer (Sigma), splenocytes were
washed and resuspended in Lymphocyte Medium [R-10 (RPMI
1640 supplemented with 10% FCS, penicillin/ streptomycin),
20 mM HEPES and 15 mM 2-mercaptoethanol] at concentration
of 2610
7 cells/ml.
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HPLC-purified, overlapping 15- by 11-mer peptides spanning the
entire HIVCONSV protein were obtained from Sigma Genosys.
Peptides were at least 80% pure as verified by mass spectrometry.
Individual peptides corresponding to epitopes were synthesised in
an in-house facility (Weatherall Institute of Molecular Medicine,
Oxford). All peptides were dissolved in DMSO (Sigma) at
a concentration of 50 mg/ml, and stored at 280uC.
Murine intracellular cytokine staining
Two million splenocytes were added to each well of a 96-well round-
bottomed plate (Falcon) and pulsed with peptides or peptide pools
and kept at 37uC, 5% CO2 for 90 min, followed by the addition of
GolgiStop
TM (BD Biosciences). After a further 5-h incubation,
reaction was terminated, the cells washed with FACS wash buffer
(PBS, 2% FCS, 0.01% Azide) and blocked with anti-CD16/32 (BD
Biosciences) at 4uC for 30 min. All subsequent antibody stains were
performed using the same conditions. Cells were then washed and
stained with anti-CD8-PerCP or anti-CD4-PerCP (BD Biosciences),
washed again and permeablized using the Cytofix/Cytoperm
TM kit
(BD Biosciences). Perm/Wash buffer (BD Biosciences) was used to
wash cells before staining with anti-IL-2-FITC, anti-TNF-a-PE and
anti-IFN-c-APC (BD Biosciences). Cells were fixed with CellFIX
TM
(BD) and stored at 4uC until analysis.
Murine ELISPOT assay
The ELISPOT assay was performed using the Becton Dickinson
IFN-c ELISPOT kit according to the manufacturer’s instructions.
The membranes of the ELISPOT plates (BD Immunospot
TM
ELISPOT Plates) were coated with purified anti-mouse IFN-c
antibody diluted in PBS to a final concentration of 5 mg/ml at 4 uC
overnight, washed once in R-10, and blocked for 2 h with
R-10. A total of 2.5610
5 splenocytes were added to each well,
stimulated with or without peptide for 16 h at 37uC, 5% CO2 and
lysed by incubating 2x with deionized water for 5 min. Wells were
then washed 3x with PBS 0.05% Tween-20, incubated for 2 h
with a biotinylated anti-IFN-c antibody diluted in PBS 2% FCS to
a final concentration of 2 mg/ml, washed 3x in PBS 0.005%
Tween-20 and incubated with 50 mg/ml horseradish peroxidase-
conjugated to avidin in PBS 2% FCS. Wells were washed 4x with
PBS 0.005% Tween-20 and 2x with PBS before incubating with
an AEC substrate solution [3-amino-9-ethyl-carbazole (Sigma)
dissolved at 10 mg/ml in Dimethyl formaldehyde and diluted to
0.333 mg/ml in 0.1 M acetate solution (148 ml 0.2 M acetic acid
and 352 ml 0.2 M sodium acetate in 1 liter pH 5.0) with 0.005%
H2O2]. After 5–10 min, the plates were washed with tap water,
dried and the resulting spots counted using an ELISPOT reader
(Autoimmune Diagnostika GmbH).
51Chromium-release assay
Isolated mouse splenocytes were restimulated in vitro with 2 mg/ml
of peptide in the Lymphocyte Medium for 5 days, at 37uC5 %
CO2. On day 5 the cells were washed three times in R-0 and
diluted two-fold in a 96-well U-bottom plate (Nunc) to yield the
different effector to target ratios. ELA A2-K
d or JK A2-K
d target
cells were labelled with
51Chromium at 37uC5 %C O 2 for 90 min
with or without appropriate peptide, washed three times with R-0,
added to the effector cells at 5610
3 target cells per well, and
incubated at 37uC5 %C O 2 for 4–6 h. The percentage of peptide-
specific lysis was calculated as [(sample release-spontaneous
release)/(total release-spontaneous release)]6100. The spontane-
ous release was less than 10% of the maximum release.
Human PBMC samples
For healthy lab subjects, PBMC separation was performed within
2 h of blood receipt. Blood was layered onto Ficoll (Sigma-
Aldrich) and centrifuged (40 min, 400 g, without brake) at room
temperature. Following centrifugation, the cellular interface was
removed, diluted in Hanks buffer (Sigma-Aldrich), and re-
centrifuged. Cryopreserved PBMC samples from vaccine clinical
trial participants in Oxford and African patients were used for
detection of HIV-1-specific effectors. Cells were washed once
more with 50 ml RPMI (Sigma-Aldrich) and then suspended in
10 ml RPMI for counting. Cells were counted using a Coulter Z1
Counter (Beckman-Coulter). Trypan blue exclusion (Sigma-
Aldrich) was used to estimate the percentage of viable cells. All
studies involving human samples were approved by local Ethical
Review Panels and all patients gave an informed consent for
donation of blood samples.
Short-term culture of PBMC
Short-term cell lines were set up as described previously[31].
Briefly, on day 0, fresh or frozen PBMCs were washed three times
in R-0 and resuspended at 2610
6 cells/ml in RAB-10 (RPMI
1640, 10% human AB serum) supplemented with 25 ng/ml of
IL-7 (R&D Systems). Twelve-well tissue culture plates (Nunc) were
seeded with 0.9 ml of the PBMC suspension. Hundred ml of either
Pool 1-3, Pool 4-6, or the FEC Pool (positive control of Flu-EBV-
CMV CD8 epitopes) was added to each well for a final con-
centration of 1.5 mg/ml for each individual peptide. On day 3 and
7, 1800 IU of IL-2 (Chiron) were added to each well, as well as
1 ml of RAB-10 on day 7. On day 10, cells are washed twice in
PBS, resuspended in fresh RAB-10 and rested for 26 to 30 h. Cells
were subsequently tested for IFN-c production in an ELISPOT
assay with or without CD8
+ cell depletion as described below.
CD8
+ cell depletion
CD8
+ cells were depleted using the Dynabead Depletion Kit
(Dynal) following the manufacturer’s recommendation. Briefly,
PBMCs were resuspended in a small volume with biotinylated
anti-CD8 monoclonal antibody (BD Biosciences), incubated for
20 min at 4uC, the excess antibody was then washed off, cells were
incubated with Dynabeads for 20 min at room temperature on an
orbital shaker, and separated by a magnet. The depleted cells were
collected and washed twice.
IFN-c ELISPOT assay
PVDF membrane ELISPOT 96-well plates (Nunc) were pre-wet
by dispensing 50 ml of 70% ethanol, incubating at room
temperature for 5 min and washing three times with endotoxin
free PBS (Sigma). Plates were then coated overnight at 4uC with
50 mlo fa1 0mg/ml purified anti-human IFN-c antibody solution
in PBS. Plates were blocked with R-10 for 2 h, 80,000 cells/wells
in 50 ml of R-10 were added to each well (40,000 cells for FEC
lines), as well as the appropriate peptide pool in 50 ml of R-0 (final
concentration of 1.5 mg/ml or each individual peptide) or relevant
controls from pre-aliquoted peptide plates. Plates were incubated
at 37uC, 5% CO2 for 14 to 18 h. Wells were then washed six times
with PBS 0.05% tween-20 and incubated for 2 h with a biotiny-
lated anti-IFN-c antibody diluted in PBS 0.5% BSA to a final
concentration of 1 mg/ml. Wells were washed again six times with
PBS 0.05% tween-20 and incubated for 1 h with a horseradish
peroxidase complex (Vector Laboratories) in PBS. Wells were
washed four times with PBS 0.05% tween-20, two times with PBS,
and incubated for 4 min with an AEC substrate solution (3-amino-
9-ethyl-carbazole (Sigma) dissolved at 10 mg/ml in dimethyl
A Universal HIV-1 Vaccine
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[148 ml 0.2 M acetic acid and 352 ml 0.2 M sodium acetate in 1l
of distilled water, pH 5] with 0.005% H2O2). Wells were finally
washed three to five times with tap water to stop the reaction,
dried,andspotswerecountedonanELISPOTreader(Autoimmune
Diagnostika). Results were expressed as Spot Forming Units per
million cells (SFU/10
6 cells). Responses were considered positive if
they were four times higher than background (no peptide) and if the
background was less than 100 SFU/10
6 cells.
Statistical analysis
An unpaired student t-test was used to determine significant
difference between the averages of mock-stimulated splenocytes
and splenocytes restimulated with a particular peptide in ICS
assays in BALB/c mice, and between the averages of mock-
stimulated splenocytes and splenocytes restimulated with a partic-
ular peptide pool in IFN-c ELISPOT assays in HHD mice, PBMC
unpulsed and peptide-pulsed, and was performed using the
program available at http://www.physics.csbsju.edu/stats/t-test.
html. Responses were defined as positive if p,0.05.
RESULTS
Design of the HIVCONSV immunogen
A novel immunogen, termed HIVCONSV (for conserved), was
designed as a chimaeric protein and assembled from the most
highly conserved domains among the HIV-1 clade A, B, C and D
proteomes. First, a decision was taken that the HIVCONSV gene
should be approximately 2.5 kbp in size, which makes it suitable
for most currently used genetic vaccine vectors and is likely to
support a high protein expression. Two and a half thousand
nucleotides translated into fourteen, 27- to 128-aa-long, most
conserved regions of the HIV-1 proteins (Fig. 1A). The centralized
sequence method was employed and the HIVCONSV immunogen
was assembled from segments derived from one of the four within-
clade consensus sequences (Fig. 1B) to reflect the fact that even the
most conserved regions of HIV-1 are somewhat variable. It should
be noted that because these regions are so highly conserved, often
the consensus for one clade perfectly matched the consensus
sequences of the other clades or indeed the group M (Fig. 1C),
enhancing the potential for eliciting globally relevant cross-reactive
responses. To keep the vaccine simple and minimize occurrence of
immune interference of T cell responses while ensuring a good
coverage of all the four major clades, we alternated the clades of
individual segments in the ‘string’ (Fig. 1C and D). Epitopes
recognized by rhesus macaque and mouse CD8
+ T cells, and
a mAb[47–49] were added to the C-terminus of the HIVCONSV
immunogen (Fig. 1B–D), to facilitate the vaccine pre-clinical
development.
Alignments of the HIVCONSV immunogen with the global HIV-
1 sequences of group M including recombinant forms revealed
that at least half of the sequences in the Los Alamos database are
identical to fragments 6 and 8 (the median distance=0), while
fragments 2, 3, 10, 11, and 12 differ in less than 3% of their aa
positions when compared to half of the sequences (median ,0.03).
The largest distance from the circulating global sequences
displayed fragment 9 with differences in just over 7% aa positions.
Conserved HIV-1 protein regions were included into the
HIVCONSV immunogen irrespective of whether of not they
contained known T cell epitopes, however, every conserved
fragment in the HIVCONSV contains at least one known human
epitope (Fig. 1F). In fact, 270 (24%) of the 1112 distinct published
CD8
+ T cell epitopes smaller than 12 aa described in the Los
Alamos HIV-1 database are embedded in these fragments. Even
though most epitopes in the literature have been defined using
clade B reagents and the HIVCONSV immunogen is an assemblage
of HIV-1 clade A, B, C, and D consensus fragments, still 192
(71%) of these 270 HIVCONSV epitopes are identical to an
experimentally defined epitopes and additional 59 (22%) differ by
only one aa, so that 251 (93%) epitopes differ by no more than
a single-aa difference from a known epitope and thus may elicit
a cross-reactive response.
Vaccine construction and basic immunogenicity
The HIVCONSV gene was made synthetically using ‘humanized’ aa
codons[50] and its open-reading frame was preceded by
a consensus Kozak sequence to -12 nucleotides[51] to maximize
protein expression. A Met start codon was added to the first
fragment. For initial studies, the gene was inserted into plasmid
pTH DNA, human adenovirus serotype 5 (AdHu5) and modified
vaccinia virus Ankara (MVA) vectors described previously[52] to
yield pTH.HIVCONSV, AdHu5.HIVCONSV and MVA.HIVCONSV
vaccines, respectively. The HIVCONSV protein expression was
demonstrated by immunofluorescence of transiently transfected or
r
Figure 1. The HIVCONSV immunogen. (A) Localization of the 14 most highly conserved regions of the HIV-1 proteome. The numbers written vertically
under each fragment boundary indicate the first and last aa positions using the HXB2 reference strain numbering (http://www.hiv.lanl.gov/content/
hiv-db/LOCATE/locate.html). (B) Predicted aa sequence of the the HIVCONSV immunogen with indicated fragment numbers. (C) Summary of the
fragments including: the fragment number; the protein in which it was embedded; the clade of the consensus sequence selected for inclusion in the
immunogen, alternating between clades A–D; additional clades that have identical HIVCONSV; and position numbers in the chimeric vaccine. The
number of additional clades with identical consensus sequences to selected clade reflects the high level of conservation in these regions, and is
encouraging in terms of the global potential of the vaccine. The consensus sequences compared were to the M group consensus, clades A–K, and
three very common recombinant circulating forms CRF01 (common in Asia and Africa), CRF02 (common Africa), CRF08 (common in China) retrieved
from the Los Alamos database 2004 consensus alignment (http://www.hiv.lanl.gov/content/hiv-db/CONSENSUS/M_GROUP/Consensus.html). (D)
Schematic representation of the HIVCONSV immunogen (not drawn to scale) indicating clade anternation (above), overlapping peptide pool derivation
and protein origin by colour coding. (E) Hamming distances between the HIVCONSV antigen fragments and the global circulating viral sequences. The
full M group alignment, including recombinant sequences, was used for the comparison. The Los Alamos database alignment contains only one
sequence person, and contains sequences from between 600 and 1000 individuals in these proteins. The Hamming distance range for 95% of the
sequences relative to the vaccine immunogen is given by the vertical lines. The distances between the full length natural proteins were then
calculated relative to HXB2 reference strain Env, Vif, Gag and Pol sequences for comparison. Distance measures are minimal estimates, as gaps
inserted in regions where insertions and deletions occur were not counted. (F) Numbers of known CD8
+ T cell epitopes (defined to within 12 aa or
less in the Los Alamos HIV-1 database) in each of the 14 conserved protein fragments included in the HIVCONSV immunogen are shown. When more
than one HLA class I presenting molecules can present the same HIV-1 epitope, then each is counted as a distinct epitope; if more than one sequence
variant has been described as an epitope presented by the same class I molecule, then these are counted as a distinct epitopes; however, if an HLA
serotype and genotype that are potentially the same are each described as presenting the same epitope (like A2 and A*0201) they are scored as
a single epitope.
doi:10.1371/journal.pone.0000984.g001
A Universal HIV-1 Vaccine
PLoS ONE | www.plosone.org 5 October 2007 | Issue 10 | e984infected human embryonic kidney cells 293T using the mAb C-
terminal tag (Fig. 2A–D). Using immunodominant epitope H, also
known as P18-I10[49] and restricted by H-2D
d and L
d, the
immunogenicities of individual vaccines and their heterologous
prime-boost combinations were confirmed in the BALB/c mice.
This demonstrated a strong priming with the pTH.HIVCONSV
DNA and ability to boost responses by heterologous vaccine
vectors measured by ex vivo interferon (IFN)-c ELISPOT (Fig. 2E)
and
51Cr-release (not shown) assays. Particularly strong responses
were elicited by the pTH DNA-rAdHu5-rMVA regimen (further
designated DAM) delivering HIVCONSV reaching a mean of 3375
spot-forming units (SFU)/10
6 of freshly isolated splenocytes.
Breadth of HIVCONSV vaccine-induced immune
responses in the BALB/c mice
The HIVCONSV chimaeric protein is not a natural protein, and the
new context resulting from concatenating the fragments may
impact the processing of intact epitopes that are embedded within
the fragments. It was therefore important to demonstrate that
HIVCONSV can induce T cell responses in mice and that epitopes
recognized by human HLA-restricted T cells can be generated.
We noted, as previously, that the response to the added H epitope
dominated the T cell response in BALB/c mice (Fig. 3A). To avoid
the H epitope domination of the T cell responses in the BALB/c
mice[18,53], vaccines expressing HIVCONSVdH immunogen with
the H epitope deleted were constructed. Groups of BALB/c mice
were immunized using the two strongest heterologous regimens
from the previous experiment and the breadth of induced T cells
was assessed using six pools of 32 peptides (15-mer overlapping by
11 amino-acid residues) corresponding to the whole HIVCONSV
protein (Fig. 1D). While weak responses were observed following
the DM regimen, higher frequencies of T cells recognizing at least
5 peptide pools were elicited by the DAM regimen (Fig. 3A, left
and middle panels). In both instances, responses to pools 1–4 were
dominated by the H epitope in pool 6 and were much stronger
when the HIVCONSVdH immunogen was used (Fig. 3A, right
panel). Next, we showed that the DM regimen of the
HIVCONSVdH vaccines induced both CD8
+ and CD4
+ T cells,
which could produce IFN-c and IL-2 in response to antigenic
stimuli (Fig. 3B). Following identification of the individual pool
peptides, minimal previously identified peptides were confirmed
for some responses minimal epitopes[53] (Fig. 3C). Further
analysis demonstrated elicitation of high quality T cells capable
of production of IFN-c, IL-2 and TNF-a (Fig. 3D) and killing of
targets sensitized with MHC class I-restricted peptides (not shown).
Finally, using the HIVCONSV vaccines and the one CD4
+ and five
CD8
+ T-cell epitopes, various dual and triple heterologous
regimens were directly compared. This indicated that at the doses
used, triple schedules were more immunogenic than the dual ones
and indicated the superiority of DAM (Fig. 3E).
HIVCONSV vaccine-induced HLA-A2-restricted
responses in transgenic mice
As a prelude to experiments in humans, we used genetically
modified mouse strain HHD, which expresses as the only MHC
class I molecule chimaeric human (a-1 and a-2) and mouse (a-3)
HLA-A*0201 heavy chain covalently linked to the human b2m
light chain. We used the most potent DAM regimen of the
HIVCONSV vaccines for induction of HLA-A*0201-restricted T cells
and detected responses in ex vivo IFN-c ELISPOT assay recognizing
two peptide pools (Fig. 4A). Using the same assay, the fine
specificities of these responses were mapped to two previously
described[54,55] although relatively uncommon, minimal epitopes
(Fig. 4B), which were confirmed in a
51Cr-release assay on murine
and human target cell lines expressing the HLA-A*0201 molecule.
The epitopes were fully conserved in three out of the four consensus
clade sequences, but the one aa substitution of the one outlier clade
did not affect the killing (Fig. 4C). Note that the VIYQYMDDLY
epitope encompasses the reverse transcription active site.
Generation of HIVCONSV-specific responses in natural
HIV-1 infection
Next, we demonstrated that natural HIV-1 infection generally leads
to generation of HIVCONSV-specific T cell responses, although these
are usually smaller than the commonly seen immunodominant
responses to epitopes in the more variable regions of HIV-1 and
required in vitro expansions. All blood donors were tissue typed and
where possible, the clade of their virus was identified (Table 1). In
order to maximize sensitivity, PBMCs from infected patients were
expanded in culture in the presence of HIVCONSV-derived peptide
pools prior to the IFN-c ELISPOT assay as described previous-
ly[31]. In this highly sensitive assay, 0 of 9 healthy HIV-1/2-
Figure 2. HIVCONSV protein expression in human cells and basic
immunogenicity. A histochemical and DAPI staining of 293T cells
transiently transfected with pTH.HIVCONSV DNA (A), or infected with
MVA.HIVCONSV (B) or AdHu5.HIVCONSV (C and D). HIVCONSV protein
expression was detected using mAb tag Pk at the C-terminus of the
immunogen and a primary anti-Pk mAb followed by secondary FITC- (A
and B) or AlexaFluor584- (C and D) conjugated detection antibodies.
The AdHu5.HIVCONSV vaccine also expressed GFP, which co-localized
with the HIVCONSV expression (D). (E) BALB/c mice were immunized
using the regimen indicated below, and the HIVCONSV-induced T cell
responses were assessed in an ELISPOT assay using the H epitope.
Results are shown as a mean6SD (n=4). U–unimmunized; D–
pTH.HIVCONSV DNA; A–AdHu5.HIVCONSV; and M–MVA.HIVCONSV. For doses
and timing, see Methods.
doi:10.1371/journal.pone.0000984.g002
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PLoS ONE | www.plosone.org 6 October 2007 | Issue 10 | e984Figure 3. Breadth of HIVCONSV-induced T cell responses in BALB/c mice. Mice were immunized using the regimen and immunogen indicated above
(A, B and C) or below (D) the graphs and the HIVCONSV-specific responses were determined in ex vivo ELISPOT (A and E) or ICS (B and D) assays
detecting the indicated cytokines and using for restimulation overlapping peptide pools schematically shown in Fig. 1D (A and B) or individual
epitope peptides (D and E). (C) Identified peptides or epitope sequences and their origin, name and T cell reactivity. In (D): white–IFN-c; black–IL-2;
stripy-IFN-c+IL-2; and grey–TNF-a; *-responses significantly above the no-peptide background (p,0.05). In (E): white–no peptide followed from left to
right by epitopes H, G1, G2, P1, P2 and P3. Results are shown as a mean6SD (n=4). For doses and timing, see Methods.
doi:10.1371/journal.pone.0000984.g003
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PLoS ONE | www.plosone.org 7 October 2007 | Issue 10 | e984uninfected lab volunteers had detectable responses to HIVCONSV
peptides, while 13 of 13 HIV-1-infected patients had HIVCONSV-
specific memory T cells (Fig. 5A). In all five tested patients for whom
we had sufficient frozen PBMC, depletion of CD8
+ cells demon-
strated thatthese responses weremediated byCD8
+ T cells (Fig. 5B).
These responses were broad and the median magnitude of all the
HIV-1-infected patients for each peptide pool ranged between 1,000
and 3,500 SFU per 10
6 cells in the cultured IFN-c ELISPOT assay
(Fig. 5C). With the exception of patient 020, twelve HIV-1-infected
individuals responded to at least two peptide pools and 6 to three or
more (Fig. 5D). Thus, conserved regions of the HIV-1 proteome
included in the HIVCONSV immunogen served as a source of
T cell epitopes immunogenic during the course of natural HIV-1
infection.
DISCUSSION
A critical and contentious issue in HIV-1 vaccinology is how the
vaccine-induced T cell responses will cope with both the intra- and
inter-clade virus variabilities. Here, we describe a design and pre-
clinical evaluation of vaccine immunogen HIVCONSV, which is
based on the 14 most conserved regions of the HIV-1 proteome.
These regions are well populated with known though less dominant
CD8
+ T cellepitopes, whichare highly conserved. Wedemonstrated
in BALB/c and HLA-A*0201-transgenic mouse strains that this
vaccine immunogen can serve as a source of immunogenic epitopes.
Furthermore, we detected HIV-1-specific memory T cells that could
recognize HIVCONSV-derived peptides in 13/13 HIV-1-infected
patients proving that HIVCONSV -specific responses are commonly
generated during natural HIV-1 infection.
Figure 4. HIVCONSV-induced T cell responses in HLA-A*0201-trans-
genic mice, strain HHD. (A) Mice were immunized using the DAM
regimen and the vaccine-induced responses were detected in an ex vivo
ELISPOT assay. Results are shown as a mean6SD (n=4). For doses and
timing, see Methods. (B) Identified epitope peptides and their origin. (C)
Killing of murine EL4 A2-K
d (top) and human JK A2-K
d (bottom) target
cells sensitized with the shown peptides in a
51Cr-release assay after a 5-
day in vitro peptide re-stimulation. Black, grey and white bars indicated
effector to target ratios of 100, 50 and 25 to 1, respectively.
doi:10.1371/journal.pone.0000984.g004
Table 1. Tissue types and infecting viruses of human blood
donors
......................................................................
Donor No. HLA HIV-1 Clade
A* B* Cw*
001
a 1, 11 44, 51 7, 15 n.a.
002
a 2, 3 7, 13 6, 7 n.a.
003
a 1, 24 15, 18 3, 12 n.a.
004
a 1, 0201 7, 40 2, 7 n.a.
005
a 2, 3 7, 15 3, 7 n.a.
006
a 1, 0301 7, 08 7, 97 n.a.
007
a 2, 23/24 57, 42 2, 17 n.a.
008
a 1, 2 5001, 55 3, 6 n.a.
009
a 0201, 29 44, 13 6, 1601 n.a.
010
b 0102, 3303 44, 5802 n.d. B/D
011
b 2, 29 45, 5802 6, 1601 D/A2 (CRF16)
012
b 2 15, 4402 3, 5 B
013
b 01, 11 18, 35 4, 7 B
014
b 24, 3401 40, 56 1, 4 B/C (CFR07)
015
c 3, 11 15, 4402 0303, 05 B
016
c 2601, 6802 70, 81 03, 04 n.d.
017
c 24 7, 18 7, 16 n.d.
018
c 1, 6801 5001, 1517 6, 7 n.d.
019
c 2601, 6802 70, 81 3, 4 n.d.
020
c 29, 32 7, 4401 1601 n.d.
021
c 0201, 0205 7, 18 n.d. n.d.
022
c 03, 11 4201, 5301 4, 17 C
aHIV-1/2-uninfected subjects
bUK HIV-1-infected patients vaccinated with HIVA vaccines
cPatients infected with HIV-1 in Africa [4]
n.a. – not applicable; n.d. not done
doi:10.1371/journal.pone.0000984.t001
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PLoS ONE | www.plosone.org 8 October 2007 | Issue 10 | e984Pathogens such as HIV-1 with highly variable genomes still
have relatively conserved regions of the proteome, which are
structurally or functionally important. Some of these regions might
reflect a lack of a selective immunological pressure, i.e. absence of
immunodominant or any epitopes that select out escape muta-
tions, although one would expect to see some background
synonymous and non-synonymous variability if there were no
fitness cost to substitutions in such regions. Here, we confirm both
in mice and humans that the conserved HIVCONSV regions are not
generally immunologically inert and contain T cell epitopes that
are often recognized, although these tend to be less immunodo-
minant than more variable epitopes in natural infection. This
subdominance may be an advantage for the vaccine strategy,
because it would allow elicitation of a T cell response that is
different from that normally stimulated by HIV-1 (which fails to
control the virus). The subdominance of many HIVCONSV
epitopes and influence of immunodominance was clearly demon-
strated in the series of BALB/c mouse immunizations using the
HIVCONSV and HIVCONSVdH immunogens where a deletion of
a single dominant ‘H’ epitope tripled the frequencies to several
previously subdominant epitopes. Although 37 HLA-A2-restricted
epitopes have been described, most patients only respond to the
same two or three of these, which are immunodominant, but
absent from the HIVCONSV immunogen [56]. Therefore, it was
encouraging that the HLA-A*0201-transgenic mice nevertheless
generated responses to 2 conserved subdominant epitopes, one of
which include the reverse transcriptase active site. It is noteworthy
that responses to some subdominant epitopes have been shown to
be more protective than that those recognizing their immunodo-
minant companions [57–59]. In natural HIV-1 infection, many of
the conserved epitopes present in this construct are subdominant
as implied by the need for expansion of patients’ PBMC prior to
the response detection. In contrast the more variable escapable
epitopes dominate to the extent that HLA type imprints changes in
virus sequence in the patient populations [60,61]. Our approach
offers the possibility of changing the natural immunodominance
by pre-infection vaccination, focusing the responses on highly
conserved epitopes more like those seen by long term non-
progressors with HLA B27 or B57 (ref. [62]).
In this work, we also directly compared various heterologous
two- or three-component vaccination regimens and found that the
most potent at the vaccine doses used was a combination of the
three employed vectors in a DNA priming followed by sequential
boosts with rHAdV-5 and rMVA, or the DAM regimen. Although
this may depend of the doses used and be immunogen specific[63],
triple prime-boost regimens were superior to the dual deliveries
and merit testing in clinical trials.
A theoretical problem with this vaccine construct, a consequence
of the chimaeric nature of the immunogen, is the possibility that
unnatural stretches of aa at the boundaries of the fragments could
also elicit T cell responses. In the work here, we did not identify
any response to a junctional epitope, although we cannot exclude
this happening with some HLA types and when the vaccine is
tested in humans these responses should be sought to ensure there
are no cases of immunodominance weakening the true anti-HIV-1
responses.
Although T cell epitopes in conserved regions of HIV-1 proteins
were identified previously[64–72] and their value for vaccine
development has been recognized[71,72], the HIVCONSV immu-
nogen has a number of unique features. The HIVCONSV
immunogen is a chimaeric protein assembled from protein regions
rather than epitopes, which enables broader coverage overlapping
epitopes presented by multiple HLA proteins; it uses consensus
sequences of the four major HIV-1 clades, which are in many
segments identical to consensus sequences from multiple clades
and this should allow a geographically broad deployment of the
HIVCONSV vaccines; it employs artificial clade consensus
sequences designed to deal with the intra-clade variability; it
Figure 5. Recognition of HIVCONSV-derived peptides by PBMC from HIV-1-infected patients. The HIVCONSV-specific memory T cells were assessed in
healthy and HIV-1-infected subjects using an IFN-c ELISPOT assay after a 10-day peptide and cytokine culture. (A) Summed frequencies of HIVCONSV-
specific cells detected in healthy (n=9) and HIV-1-infected (n=13) subjects. The bars show the group medians of 578 SFU/10
6 and 8,092 SFU/10
6 cells
for the healthy and infected subjects, respectively. (B) In five subjects indicated below, cultured PBMC were left undepleted (grey) or depleted of
CD8
+ cells (black) prior to the ELISPOT assay. The difference between undepleted (median=8,092 SFU/10
6 cells) and CD8-depleted samples
(median=550 SFU/10
6 cells) was statistically significant (p=0.0313). (C) Responses to individual HIVCONSV-derived peptide pools as shown in Fig. 1D
determined for the HIV-1-infected (grey) and healthy (black) subjects shown as medians. (D) Responses to individual peptides pools for each HIV-1-
infected patient indicated below. Bars show a mean6SD of three assay wells and ‘*’ indicates a positive response according to criteria set in Methods.
Due to sample shortage, subject 021 was not tested.
doi:10.1371/journal.pone.0000984.g005
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PLoS ONE | www.plosone.org 9 October 2007 | Issue 10 | e984combines sequences of the four clades sequentially rather than in
parallel, which avoids epitope antagonism; and through the lower
frequency of immunodominant epitopes, it favours induction of
broader T cell responses. Our initial results indicate that human T
cell responses to epitopes embedded in the chimaeric immunogen
are common, although further study is needed to indicate how
generalizable this is to other epitopes of HIVCONSV, and if the
junction regions between fragments can stimulate problematic
responses in humans. Finally, the theoretical global epitope
coverage by the HIVCONSV immunogen is narrower compared
to the considerably more complex ‘‘mosaic’’ gene strategy, but the
balance between optimizing epitope coverage and vaccine
simplicity perhaps favours our HIVCONSV approach.
The desirable, but not critical non-human primates studies with
the HIVCONSV immunogen are underway. Although the advan-
tages and disadvantages of the HIVCONSV vaccines or any of the
other methods addressing the HIV-1 diversity discussed above can
be argued theoretically and in model situations, whether or not
any of them can induce broad enough anti-HIV-1 responses to
decrease the transmission and/or reduce virus load in HIV-1-
infected vaccine recipients will be only proven in clinical trials.
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